Novo Nordisk Ends Cell Therapy Program Aimed at Type 1 Diabetes Cure
Novo Nordisk has decided to shut down its cell therapy division, which had been focused on developing a potential cure for type 1 diabetes, according to a report by Bloomberg News on Friday. The company confirmed the move in an official statement, citing its ongoing efforts to streamline operations and reduce costs across research divisions.
The decision marks a shift in Novo Nordisk’s research strategy, as the pharmaceutical giant refocuses its resources on core treatments and next-generation diabetes therapies already showing commercial success.
